Who
Lindsay Androski
President and CEO
Company insider
Files Form 4 as: President and CEO, Arbutus Biopharma; Director, Eloxx Pharmaceuticals.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Jul 2022
- Last trade
- 1 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 7 Oct 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code D | $123K24,655 at $5.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $373K116,408 at $3.20 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $46K10,456 at $4.39 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code F | $418K82,527 at $5.07 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —116,408 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,456 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —116,408 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,456 at $0.00 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $373K116,408 at $3.20 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code M | $46K10,456 at $4.39 | filing |
| 18 Sep 2026filed 23 Sep 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code F | $418K82,527 at $5.07 | filing |
| 2 Feb 2026filed 2 Feb 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,700 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,700 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 18 Mar 2025filed 20 Mar 2025 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —310,422 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ELOX Eloxx PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 16 Oct 2024filed 17 Oct 2024 | ELOX Eloxx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 24 Jan 2024filed 26 Jan 2024 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.